Effect of intraoperative intravenous esketamine on depression in infertility and pregnancy loss patients

Effect of intraoperative intravenous esketamine on depression in infertility and pregnancy loss patients - a single-center, randomized, double-blind, parallel-controlled, superiority clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000040404

Enrollment

Unknown

Registered

2020-11-28

Start date

2020-11-25

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Interventions

Esketamine group:10ml intravenous injection of 0.25mg/kg esketamine when anesthesia induction

Saline group:10ml intravenous injection of 0.9% saline when anesthesia induction

Eligibility

Sex/Gender

Female

Age

18 Years to 49 Years

Inclusion criteria

Inclusion criteria: 1. Women with infertility or pregnancy loss; 2. Aged 18-49 years old women with childbearing age; 3. ASA physical status I-II; 4. Beck-II depression score >=14 points; 5. Planned elective hysteroscopy or laparoscopic surgery.

Exclusion criteria

Exclusion criteria: 1. Body mass index >= 30kg/m2; 2. Test drug contraindications (such as severe hypertension, glaucoma, high intracranial pressure) or allergies; 3. History of illusion; 4. History of drug abuse; 5. History of other mental illnesses; 6. With obvious neurological symptoms such as dizziness, headache, blurred vision.

Design outcomes

Primary

Measure	Time frame
BDI-II (Beck-II depression) score;	—

Secondary

Measure	Time frame
STAI (state-trait anxiety inventory) score;	—

Countries

China

Contacts

Public ContactRouxuan Zhou

Shenzhen Maternity and Child Healthcare Hospital

zhourouxuan@126.com+86 13927465758

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026